<DOC>
	<DOCNO>NCT01718119</DOCNO>
	<brief_summary>The purpose study compare efficacy safety DA-3803 ( r-hCG ) Ovidrel induct final follicular maturation early luteinization woman undergo ovulation induction assist reproduction treatment</brief_summary>
	<brief_title>Clinical Trial Comparing Efficacy Safety DA-3803 Ovidrel</brief_title>
	<detailed_description>This single-blind , randomize , comparative multicentric , phase III study evaluate safety efficacy DA-3803 ( r-hCG ) comparison Ovidrel induction final follicle maturation early luteinization 180 Korean female subject undergoing superovulation . The study organize outpatient basis subject undergo assisted reproductive technology ( ART ) . The subject randomize 2 group . One group receive DA-3803 ( r-hCG ) 250mcg group receive Ovidrel® ( r-hCG ) 250mcg . Each subject group receive single injection hCG follicular development judge adequate . Oocytes retrieve 34-38 hour r-hCG injection fertilize vitro . Not 4 embryo replace . Progesterone administer daily accord center 's normal practice , start oocyte pick continue appropriate time . The subject follow treatment outcome ( negative pregnancy test pregnancy ) record .</detailed_description>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>Infertility regular ovulatory menstrual cycle : 25~35days BMI &lt; =30kg/m2 Early follicular phase serum level normal : FSH , LH , prolactin , testosterone Both ovary present clinically normal uterine cavity &lt; 3 previous ART cycle , ART cycle 2 menstrual cycle semen analysis ART possible informed couple consent With poor response gonadotrophin stimulation , ≤3 oocytes collect previous ART cycle Had previous severe ovarian hyperstimulation syndrome ( OHSS ) Polycystic ovarian syndrome ( PCOS ) Extrauterine pregnancy within last 3 month A clinically significant uncontrolled endocrine disease , chronic cardiovascular disorder , hepatic , pulmonary renal disease Known allergy , hypersensitivity contraindication FSH , hCG , progesterone GnRH antagonists medication human gonadotrophin preparation ( FSH , LH , hCG ) within 2 month participation another clinical trial within 1 month</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>